Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMMUNeOCT Study: Octreotide LAR in the Induction of Immunologic Response in Patient With Neuroendocrine Tumors: an Interventional Pharmacological Study

NCT04129255 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT04129255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04129255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMMUNeOCT Study: Octreotide LAR in the Induction of Immunologic Response in Patient With Neuroendocrine Tumors: an Interventional Pharmacological Study
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Completed
Start date
June 28, 2017
Completion date
December 1, 2019
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors